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1
The scope of the use of proton pump inhibitors (PPIs) in hemodialysis patients is really worrying because of its widespread use, often in the absence of medical supervision and its implications have potential adverse effects.
First, the use of PPIs has risen more than 500% between 2000 and 2012, and Spain has notably increased the rate of consumption in recent years, even in hemodialysis patients, that is especially high compared with other countries of the European Union. In addition, a significant percentage of prescriptions, estimated at 25% in the European Union and 70% in the United States, is not based on the approved indications. 3, 4 Second, several observational studies suggest that PPI use is associated with an increased risk of adverse health outcomes and cardiovascular (CV) events in particular.
5 There would be different interpretations to explain the association between PPIs and CV events in a patient with acute myocardial ischemia. An important opinion is based on the PPI's reduction of the capacity Kidney International Reports (2019) 4, 505-506 505
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